Skip to main content

Advertisement

SpringerLink
Log in

Can We Predict Clinical Cardiotoxicity with Cardiac Biomarkers in Patients After Haematopoietic Stem Cell Transplantation?

  • Published:
Cardiovascular Toxicology Aims and scope Submit manuscript

Abstract

The long-term prognosis of patients after haematopoietic stem cell transplantation (HSCT) has greatly improved. Cardiac complications represent unresolved and potentially life-threatening conditions in these patients. We prospectively examined 37 consecutive patients with a median age of 28 years who underwent allogeneic HSCT. Biomarkers of cardiac injury were measured serially before the conditioning regimen, the first day after HSCT and then 14, 30, 90 and 180 days after HSCT. Echocardiography was performed before and 1 month after HSCT. Eleven patients (30 %) had persistently increased NT-proBNP values, 14 patients (38 %) had only transient elevations and 12 (32 %) had no changes in NT-proBNP concentrations for a period exceeding 14 days after HSCT. Elevated NT-proBNP values at day 14 after HSCT remained an independent predictor of cardiotoxicity during the first 6 months after HSCT (P < 0.01). Patients with persistent elevations in NT-proBNP also had significant elevations in hs-cTnT concentrations (P < 0.01). Only patients with persistently increased NT-proBNP had a significant worsening in systolic and some diastolic echocardiographic parameters, and we observed in this group the highest values of both cardiomarkers during the 6-month period. Forty-five percent of these patients developed clinical manifestation of cardiotoxicity. Elevations in NT-proBNP concentrations at day 14 after HSCT can predict patients at risk of developing cardiac events during the first 6 months after HSCT. Simultaneous elevations of both cardiomarkers (NT-proBNP and hs-cTnT) persisting 14 days after HSCT had a sensitivity of 83 % and a specificity of 80.69 %.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Passweg, J. R., Baldomero, H., Gratwohl, A., Bregni, M., Cesaro, S., Dreger, P., et al. (2012). The EBMT activity survey: 1990–2010. Bone Marrow Transplantation, 47, 906–923.

    Article  CAS  PubMed  Google Scholar 

  2. Martin, P. J., Counts, G. W, Jr, Appelbaum, F. R., Lee, S. J., Sanders, J. E., Deeg, H. J., et al. (2010). Life expectancy in patients surviving more than 5 years after hematopoietic cell transplantation. Journal of Clinical Oncology, 28, 1011–1016.

    Article  PubMed Central  PubMed  Google Scholar 

  3. Bresters, D., van Gils, I. C., Kollen, W. J., Ball, L. M., Oostdijk, W., van der Bom, J. G., et al. (2010). High burden of late effects after haematopoietic stem cell transplantation in childhood: A single-centre study. Bone Marrow Transplantation, 45, 79–85.

    Article  CAS  PubMed  Google Scholar 

  4. Sun, C. L., Francisco, L., Kawashima, T., Leisenring, W., Robison, L. L., Baker, K. S., et al. (2010). Prevalence and predictors of chronic health conditions after hematopoietic cell transplantation: A report from the bone marrow transplant survivor study. Blood, 116, 3129–3139.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  5. Carver, J. R., & Desai, C. J. (2010). Cardiovascular toxicity of antitumor drugs: Dimensions of the problem in adult settings. In G. Minotti (Ed.), Cardiotoxicity of non-cardiovascular drugs (pp. 127–199). New York: Wiley.

    Chapter  Google Scholar 

  6. Chow, E. J., Wong, K., Lee, S. J., Cushing-Haugen, K. L., Flowers, M. E., Friedman, D. L., et al. (2014). Late cardiovascular complications after hematopoietic cell transplantation. Biology of Blood Marrow and Transplantation, 20(6), 794–800. doi:10.1016/j.bbmt.2014.02.012.

    Article  Google Scholar 

  7. Monsuez, J. J. (2012). Detection and prevention of cardiac complications of cancer chemotherapy. Archives of Cardiovascular Diseases, 105, 593–604.

    Article  PubMed  Google Scholar 

  8. Herman, E. H., Zhang, J., Lipshultz, S. E., Rifai, N., Chadwick, D., Takeda, K., et al. (1999). Correlation between serum levels of cardiac troponin-T and the severity of the chronic cardiomyopathy induced by doxorubicin. Journal of Clinical Oncology, 17, 2237–2243.

    CAS  PubMed  Google Scholar 

  9. Januzzi, J. L., Van Kimmenade, R., Lainchbury, J., Bayes-Genis, A., Ordonez-Llanos, J., Santalo-Bel, M., et al. (2006). NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: An international pooled analysis of 1256 patients: The International Collaborative of NT-proBNP Study. European Heart Journal, 27(3), 330–337.

    Article  CAS  PubMed  Google Scholar 

  10. Albini, A., Pennesi, G., Donatelli, F., Cammarota, R., De Flora, S., & Noonan, D. M. (2010). Cardiotoxicity of anticancer drugs: The need for cardio-oncology and cardio-oncological prevention. Journal of the Egyptian National Cancer Institute, 102, 14–25.

    Article  CAS  Google Scholar 

  11. Snowden, J. A., Hill, G. R., Hunt, P., Carnoutsos, S., Spearing, R. L., Espiner, E., et al. (2000). Assessment of cardiotoxicity during haemopoietic stem cell transplantation with plasma brain natriuretic peptide. Bone Marrow Transplantation, 26, 309–313.

    Article  CAS  PubMed  Google Scholar 

  12. Niwa, N., Watanabe, E., Hamaguchi, M., Kodera, Y., Miyazaki, H., Kodama, I., et al. (2001). Early and late elevation of plasma atrial and brain natriuretic peptides in patients after bone marrow transplantation. Annals of Hematology, 80, 460–465.

    Article  CAS  PubMed  Google Scholar 

  13. Masuko, M., Ito, M., Kurasaki, T., Yano, T., Takizawa, J., Toba, K., et al. (2007). Plasma brain natriuretic peptide during myeloablative stem cell transplantation. Internal Medicine, 46, 551–555.

    Article  PubMed  Google Scholar 

  14. Horacek, J. M., Pudil, R., Tichy, M., Jebavy, L., Zak, P., Slovacek, L., et al. (2007). Biochemical markers and assessment of cardiotoxicity during preparative regimen and hematopoietic cell transplantation in acute leukemia. Experimental Oncology, 29, 343–347.

    Google Scholar 

  15. Sandri, M. T., Salvatici, M., Cardinale, D., Zorzino, L., Passerini, R., Lentati, P., et al. (2005). N-terminal pro-B-type natriuretic peptide after high-dose chemotherapy: A marker predictive of cardiac dysfunction? Clinical Chemistry, 51, 1405–1410.

    Article  CAS  PubMed  Google Scholar 

  16. Roziakova, L., Bojtarova, E., Mistrik, M., Dubrava, J., Gergel, J., Lenkova, N., et al. (2012). Serial measurements of cardiac biomarkers in patients after allogeneic hematopoietic stem cell transplantation. Journal of Experimental and Clinical Cancer Research, 31, 13. doi:10.1186/1756-9966-31-13.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  17. Mavinkurve-Groothui, A. M., Kapusta, L., Nir, A., & Groot-Loonen, J. (2008). The role of biomarkers in the early detection of anthracycline-induced cardiotoxicity in children: A review of the literature. Pediatric Hematology and Oncology, 25, 655–664.

    Article  Google Scholar 

  18. Poutanen, T., Tikanoja, T., Riikonen, P., Silvast, A., & Perkkiö, M. (2003). Long-term prospective follow-up study of cardiac function after cardiotoxic therapy for malignancy in children. Journal of Clinical Oncology, 21, 2349–2356.

    Article  CAS  PubMed  Google Scholar 

  19. Daugaard, G., Lassen, U., Bie, P., Pedersen, E. B., Jensen, K. T., Abildgaard, U., et al. (2005). Natriuretic peptides in the monitoring of anthracycline induced reduction in left ventricular ejection fraction. European Journal of Heart Failure, 7, 87–93.

    Article  CAS  PubMed  Google Scholar 

  20. Suter, T. M., & Ewer, M. S. (2013). Cancer drugs and the heart: Importance and management. European Heart Journal, 34, 1102–1111.

    Article  CAS  PubMed  Google Scholar 

  21. van Dalen, E. C., Caron, H. N., Dickinson, H. O., & Kremer, L. C. (2011). Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database of Systematic Reviews. doi:10.1002/14651858.CD003917.pub4.

  22. Curigliano, G., Cardinale, D., Suter, T., Plataniotis, G., de Azambuja, E., Sandri, M.T., Criscitiello, C., Goldhirsch, A., Cipolla, C., Roila, F.; ESMO Guidelines Working Group. (2012). Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO clinical practice guidelines. Annals of Oncology, 23, 155–166.

    Google Scholar 

  23. Sherief, L. M., Kamal, A. G., Khalek, E. A., Kamal, N. M., Soliman, A. A., & Esh, A. M. (2012). Biomarkers and early detection of late onset anthracycline-induced cardiotoxicity in children. Hematology, 17, 151–156.

    Article  PubMed  Google Scholar 

  24. Romano, S., Fratini, S., Ricevuto, E., Procaccini, V., Stifano, G., Mancini, M., et al. (2011). Serial measurements of NT-proBNP are predictive of not-high-dose anthracycline cardiotoxicity in breast cancer patients. British Journal of Cancer, 105, 1663–1668.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  25. Sawaya, H., Sebag, I. A., Plana, J. C., Januzzi, J. L., Ky, B., Cohen, V., et al. (2011). Early detection and prediction of cardiotoxicity in chemotherapy-treated patients. American Journal of Cardiology, 107, 1375–1380.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  26. Sawaya, H., Sebag, I. A., Plana, J. C., Januzzi, J. L., Ky, B., Tan, T. C., et al. (2012). Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab. Circulation Cardiovascular Imaging, 5, 596–603.

    Article  PubMed Central  PubMed  Google Scholar 

  27. Garrone, O., Crosetto, N., Nigro, C. L., Catzeddu, T., Vivenza, D., Monteverde, M., et al. (2012). Prediction of anthracycline cardiotoxicity after chemotherapy by biomarkers kinetic analysis. Cardiovascular Toxicology, 12(2), 135–142.

    Article  CAS  PubMed  Google Scholar 

  28. Cardinale, D., Lamantia, G., & Cipolla, C. M. (2006). Troponin I and cardiovascular risk stratification in patients with testicular cancer. Journal of Clinical Oncology, 24, 3508.

    Article  PubMed  Google Scholar 

  29. Cardinale, D., Sandri, M. T., Colombo, A., Boeri, M., Lamantia, G., Civelli, M., et al. (2004). Prognostic value of Troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation, 109, 2749–2754.

    Article  CAS  PubMed  Google Scholar 

  30. Cardinale, D., Sandri, M. T., Martinoni, A., Tricca, A., Civelli, M., Lamantia, G., et al. (2000). Left ventricular dysfunction predicted by early troponin l release after high-dose chemotherapy. Journal of the American College of Cardiology, 36, 517–521.

    Article  CAS  PubMed  Google Scholar 

  31. Ky, B., Putt, M., Sawaya, H., French, B., Januzzi, J. L, Jr, Sebag, I. A., et al. (2014). Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab. Journal of the American College of Cardiology, 63(8), 809–816.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  32. Cardinale, D., Colombo, A., Torrisi, R., Sandri, M. T., Civelli, M., Salvatici, M., et al. (2010). Trastuzumab-induced cardiotoxicity: Clinical and prognostic implications of troponin I evaluation. Journal of Clinical Oncology, 28(25), 3910–3916.

    Article  CAS  PubMed  Google Scholar 

  33. Majhail, N. S., Rizzo, J. D., Lee, S. J., Aljurf, M., Atsuta, Y., Bonfim, C., et al. (2012). Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation. Revista Brasileira De Hematologia E Hemoterapia, 34, 109–133.

    Article  PubMed Central  PubMed  Google Scholar 

  34. Mornoş, C., & Petrescu, L. (2013). Early detection of anthracycline-mediated cardiotoxicity: The value of considering both global longitudinal left ventricular strain and twist. Canadian Journal of Physiology and Pharmacology, 91, 601–607.

    Article  PubMed  Google Scholar 

  35. Chung, W. B., Yi, J. E., Jin, J. Y., Choi, Y. S., Park, C. S., Park, W. C., et al. (2013). Early cardiac function monitoring for detection of subclinical doxorubicin cardiotoxicity in young adult patients with breast cancer. Journal of Breast Cancer, 16, 178–183.

    Article  PubMed Central  PubMed  Google Scholar 

Download references

Acknowledgments

The authors thank Marek Polomsky, MD, from the University of Rochester, New York, USA, for revision of the manuscript. This work was supported by a grant from the Scientific Grant Agency of the Ministry of Education, Slovak Republic VEGA 1/0906/14 and the grant of the European Regional Development Fund—Project FNUSA-ICRC (No. CZ.1.05/1.1.00/02.0123).

Author information

Authors and Affiliations

  1. Department of Haematology and Transfusion Medicine, University Hospital and Comenius University, Bratislava, Slovak Republic

    Lubica Roziakova, Martin Mistrik, Angelika Batorova & Eva Bojtarova

  2. Institute of Pathological Physiology, School of Medicine, Comenius University, Bratislava, Slovak Republic

    Lubica Roziakova & Beata Mladosievicova

  3. Department of Cardiovascular Diseases, International Clinical Research Center, St. Anne’s University Hospital and Masaryk University, Pekarska 53, 656 91, Brno, Czech Republic

    Peter Kruzliak

  4. Division of Non-Invasive Cardiology, University Hospital and Comenius University, Bratislava, Slovak Republic

    Juraj Dubrava

  5. Department of Clinical Biochemistry, Medirex, Bratislava, Slovak Republic

    Jozef Gergel

Authors
  1. Lubica Roziakova
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Martin Mistrik
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Angelika Batorova
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Peter Kruzliak
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Eva Bojtarova
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Juraj Dubrava
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Jozef Gergel
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Beata Mladosievicova
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Peter Kruzliak.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Roziakova, L., Mistrik, M., Batorova, A. et al. Can We Predict Clinical Cardiotoxicity with Cardiac Biomarkers in Patients After Haematopoietic Stem Cell Transplantation?. Cardiovasc Toxicol 15, 210–216 (2015). https://doi.org/10.1007/s12012-014-9286-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12012-014-9286-7

Keywords

Search

Navigation